- Home
- EUDA vs MCRB Comparison
EUDA vs MCRB Comparison
Compare EUDA & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EUDA
- MCRB
- Stock Information
- Founded
- EUDA 2021
- MCRB 2010
- Country
- EUDA Singapore
- MCRB United States
- Employees
- EUDA N/A
- MCRB N/A
- Industry
- EUDA Blank Checks
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- EUDA Finance
- MCRB Health Care
- Exchange
- EUDA Nasdaq
- MCRB Nasdaq
- Market Cap
- EUDA 149.4M
- MCRB 131.0M
- IPO Year
- EUDA N/A
- MCRB 2015
- Fundamental
- Price
- EUDA $3.76
- MCRB $0.73
- Analyst Decision
- EUDA
- MCRB Buy
- Analyst Count
- EUDA 0
- MCRB 4
- Target Price
- EUDA N/A
- MCRB $5.63
- AVG Volume (30 Days)
- EUDA 102.6K
- MCRB 2.0M
- Earning Date
- EUDA 01-01-0001
- MCRB 03-04-2025
- Dividend Yield
- EUDA N/A
- MCRB N/A
- EPS Growth
- EUDA N/A
- MCRB N/A
- EPS
- EUDA N/A
- MCRB N/A
- Revenue
- EUDA $3,811,496.00
- MCRB $126,325,000.00
- Revenue This Year
- EUDA $121.80
- MCRB N/A
- Revenue Next Year
- EUDA $78.17
- MCRB N/A
- P/E Ratio
- EUDA N/A
- MCRB N/A
- Revenue Growth
- EUDA N/A
- MCRB 12856.41
- 52 Week Low
- EUDA $1.20
- MCRB $0.54
- 52 Week High
- EUDA $6.30
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- EUDA 40.49
- MCRB 37.88
- Support Level
- EUDA $3.55
- MCRB $0.71
- Resistance Level
- EUDA $3.93
- MCRB $0.91
- Average True Range (ATR)
- EUDA 0.34
- MCRB 0.06
- MACD
- EUDA -0.09
- MCRB -0.02
- Stochastic Oscillator
- EUDA 19.66
- MCRB 8.37
About EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem aimed at making healthcare affordable and accessible, The company's proprietary unified AI platform quickly assesses a patient's medical history, triages a condition, digitally connects patients with clinicians, and predicts optimal treatment outcomes. The company caters to all stages of care, including wellness and prevention, urgent care and emergencies, pre-existing conditions, and aftercare services. The company operates in two segments namely Medical services and property management services, out of which the company derives its maximum revenue from Medical services.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.